23 results on '"Ormen B"'
Search Results
2. Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
- Author
-
Batirel, A., Balkan, I. I., Karabay, O., Agalar, C., Akalin, S., Alici, O., Alp, E., Altay, F. A., Altin, N., Arslan, F., Aslan, T., Bekiroglu, N., Cesur, S., Celik, A. D., Dogan, M., Durdu, B., Duygu, F., Engin, A., Engin, D. O., Gonen, I., Guclu, E., Guven, T., Hatipoglu, C. A., Hosoglu, S., Karahocagil, M. K., Kilic, A. U., Ormen, B., Ozdemir, D., Ozer, S., Oztoprak, N., Sezak, N., Turhan, V., Turker, N., and Yilmaz, H.
- Published
- 2014
- Full Text
- View/download PDF
3. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C
- Author
-
Usluer, G., Erben, N., Aykin, N., Dagli, O., Aydogdu, O., Barut, S., Cevik, F., Ormen, B., and Study Group (see Appendix)
- Published
- 2012
- Full Text
- View/download PDF
4. Isolated from Patients with Chronical Infection in Turkey
- Author
-
Asan, A, Sayan, M, Akhan, S, Koruk, ST, Aygen, B, Sirmatel, F, Eraksoy, H, Tuna, N, Kose, S, Kaya, A, Tulek, NE, Demir, NA, Mistik, R, Ormen, B, Korkmaz, F, Yildirmak, T, Ural, O, Aydin, M, Turgut, H, Gunal, O, and Demirturk, N
- Subjects
Chronic Hepatitis B ,HBV Polymerase ,Hepatitis B Virus ,Sequence Analysis ,HBsAg ,Antiviral Drug Resistance - Abstract
Background: Hepatitis B virus (HBV) has a high mutation rate due to its unusual replication strategy leading to the production of a large number of virions with single and double mutations. The mutations, in turn, are associated with the development of drug resistance to nucleos(t)ide analogs (NUCs) in patients before and during NUCs therapy. Objectives: The current study aimed at investigating the molecular characterization of HBV in Turkish patients with chronic hepatitis B (CHB) infection. Methods: Polymerase chain reaction (PCR) amplification and direct sequencing procedures were used to analyze mutations. The detected drug resistance mutations were divided into the nucleos(t) ide analogs primary, partial, and compensatory resistance groups. The amino acid substitutions of hepatitis B surface antigen (HBsAg) were categorized into antiviral drug - associated potential vaccine-escape mutations (ADAPVEMs) and typical HBsAg amino acid substitutions, which included hepatitis B hyperimmunoglobulin (HBIg) - selected escape mutation, vaccine escape mutation, hepatitis B misdiagnosis, and immune - selected amino acid substitutions. Results: The number of patients included in the study was 528 out of which 271 (51.3%) were treatment - naive and 351 (66.3%) were hepatitis B e antigen (HBeAg) - negative. Moreover, 325 (61.6%) were males with a mean age of 38 years (range: 18 - 69). Primary, partial, and compensatory resistance to NUCs was reported in 174 (32.9%) patients. Six different ADAPVEM motifs were determined in both treatment - naive and treatment - experienced patients, namely, sF161L/rtI169X, sE164D/rtV173L, sL172L/rtA181T, sL173F/rtA181V, sS195M/rtM204V, and sS196L/rtM204I. The prevalence of ADAPVEMs and typical HBsAg escape mutations was 5.3% (n = 28) and 34.8% (n = 184), respectively. Conclusions: The analysis of drug resistance should constitute a fundamental part of the follow - up period of patients with CHB undergone treatment with NUCs. The surveillance of development of drug resistance mutations, while receiving treatment for hepatitis B is of paramount importance to monitor and control the emerging resistance.
- Published
- 2018
5. meningitis/ventriculitis treated with intrathecal colistin
- Author
-
Ceylan, B, Arslan, F, Sipahi, OR, Sunbul, M, Ormen, B, Hakyemez, IN, Turunc, T, Yildiz, Y, Karsen, H, Karagoz, G, Tekin, R, Hizarci, B, Turhan, V, Senol, S, Oztoprak, N, Yilmaz, M, Ozdemir, K, Mermer, S, Kokoglu, OF, and Mert, A
- Subjects
Acinetobacter baumannii ,Colistin ,Meningitis ,Intratechal - Abstract
Aim: To examine the variables associated with mortality in patients with Acinetobacter baumannii-related central nervous system infections treated with intrathecal colistin. Materials and methods: This multi-centre retrospective case control study included patients from 11 centres in Turkey, as well as cases found during a literature review. Only patients with CNS infections caused by multidrug-resistant or extensively drug-resistant Acinetobacter baumannii treated with intrathecal colistin were included in this study. The variables associated with mortality were determined by dividing the patients into groups who died or survived during hospitalisation, and who died or survived from Acinetobacter meningitis. Results: Among the 77 cases enrolled in the study, 35 were found through a literature review and 42 were cases from our centres. Forty-four cases (57.1%) were male and the median age was 48 years (range: 20-78 years). Thirty-seven patients (48%) died during hospitalisation. The variables associated with increased all-cause mortality during hospitalisation included old age (odds ratio, 1.035; 95% confidence interval (Cl), 1.004-1.067; p = 0.026) and failure to provide cerebrospinal fluid sterilisation (odds ratio, 0.264; 95% confidence interval, 0.097-0.724; p = 0.01). There is a trend (P=0.062) towards higher mortality with using of meropenem during meningitis treatment. Fifteen cases (19%) died from meningitis. There were no significant predictors of meningitis-related mortality. Conclusions: The mortality rate for central nervous system infections caused by multidrug-resistant or extensively drug-resistant Acinetobacter baumannii is high. Old age and failure to provide CSF sterilisation are associated with increased mortality during hospitalisation. (C) 2016 Published by Elsevier B.V.
- Published
- 2017
6. EFFICACY OF COLISTIN AND NON-COLISTIN MONOTHERAPIES IN MULTI-DRUG RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA/SEPSIS
- Author
-
OĞUZ KARABAY, Batirel, A., Balkan, I. I., Agalar, C., Akalin, S., Alici, O., Alp, E., Alta, F. A., Altin, N., Arslan, F., Aslan, T., Bekiroglu, N., Cesur, S., Celik, A. D., Dogan, M., Durdu, B., Duygu, F., Engin, A., Engin, D. O., Gonen, I., Guclu, E., Guven, T., Hatipoglu, C. A., Hosoglu, S., Karahocagil, M., Kilic, A. U., Ormen, B., Ozdemir, D., Ozer, S., Oztoprak, N., Sezak, N., Turhan, V., Turker, N., Yilmaz, H., Karabay, O, Batirel, A, Balkan, II, Agalar, C, Akalin, S, Alici, O, Alp, E, Alta, FA, Altin, N, Arslan, F, Aslan, T, Bekiroglu, N, Cesur, S, Celik, AD, Dogan, M, Durdu, B, Duygu, F, Engin, A, Engin, DO, Gonen, I, Guclui, E, Guven, T, Hatipoglu, CA, Hosoglu, S, Karahocagil, M, Kilic, AU, Ormen, B, Ozdemir, D, Ozer, S, Oztoprak, N, Sezak, N, Turhan, V, Turker, N, Yilmaz, H, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Karabay, Oğuz, [Karabay, Oguz] Sakarya Univ, Hlth Sci Inst, Infect Dis & Clin Microbiol, TR-54000 Sakarya, Turkey -- [Batirel, Ayse] Kartal Dr Lutfi Kirdar Educ & Res Hosp, Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Balkan, Ilker Inanc -- Ozer, Serdal] Istanbul Univ, Cerrahpasa Med Fac, Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Agalar, Canan -- Alici, Ozlem] Fatih Sultan Mehmet Educ & Res Hosp, Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Akalin, Serife] Pamukkale Univ, Fac Med, Infect Dis & Clin Microbiol, Denizli, Turkey -- [Alp, Emine -- Kilic, Aysegul Ulu] Erciyes Univ, Fac Med, Infect Dis & Clin Microbiol, Kayseri, Turkey -- [Alta, F. Aybala] Diskapi Educ & Res Hosp, Infect Dis & Clin Microbiol, Ankara, Turkey -- [Altin, N. -- Cesur, Salim] Ankara Etlik Educ & Res Hosp, Infect Dis & Clin Microbiol, Ankara, Turkey -- [Arslan, Ferhat] Istanbul Medipol Univ, Fac Med, Infect Dis, Istanbul, Turkey -- [Aslan, Turan] Bezmi Alem Univ, Fac Med, Infect Dis, Istanbul, Turkey -- [Bekiroglu, Nural] Marmara Univ, Fac Med, Biostat, Istanbul, Turkey -- [Celik, Aygul Dogan] Trakya Univ, Fac Med, Infect Dis, Edirne, Turkey -- [Dogan, Mustafa] Namik Kemal Univ, Fac Med, Infect Dis & Clin Microbiol, Tekirdag, Turkey -- [Durdu, Bulent] Bakirkoy Sadi Konuk Educ & Res Hosp, Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Duygu, Fazilet] Gaziosmanpasa Univ, Fac Med, Infect Dis & Clin Microbiol, Tokat, Turkey -- [Engin, Aynur] Cumhuriyet Univ, Fac Med, Infect Dis & Clin Microbiol, Sivas, Turkey -- [Engin, Derya Ozturk] Haydarpasa Numune Educ & Res Hosp, Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Gonen, Ibak] Suleyman Demirel Univ, Fac Med, Infect Dis & Clin Microbiol, TR-32200 Isparta, Turkey -- [Guven, Tumer] Ankara Ataturk Educ & Res Hosp, Infect Dis & Clin Microbiol, Ankara, Turkey -- [Hatipoglu, Cigdem Ataman] Ankara Educ & Res Hosp, Infect Dis & Clin Microbiol, Ankara, Turkey -- [Hosoglu, Salih] Dicle Univ, Fac Med, Infect Dis & Clin Microbiol, Diyarbakir, Turkey -- [Karahocagil, Mustafa] Yuzuncu Yil Univ, Fac Med, Infect Dis & Clin Microbiol, Van, Turkey -- [Ormen, Bahar] Izmir Ataturk Educ & Res Hosp, Infect Dis & Clin Microbiol, Izmir, Turkey -- [Ozdemir, Davut -- Sezak, Nurbanu -- Turker, N.] Duzce Univ, Educ & Res Hosp, Infect Dis & Clin Microbiol, Duzce, Turkey -- [Oztoprak, Nefise] Antalya Educ & Res Hosp, Infect Dis & Clin Microbiol, Antalya, Turkey -- [Turhan, Vedat] GATA Haydarpasa Educ & Res Hosp, Infect Dis & Clin Microbiol, Istanbul, Turkey -- [Yilmaz, Hava] Ondokuz Mayis Univ, Fac Med, Infect Dis & Clin Microbiol, Samsun, Turkey, Karabay, Oguz -- 0000-0003-0502-432X, and DURDU, BÜLENT
- Subjects
Acinetobacter infection ,Acinetobacter baumannii ,antibiotic resistance ,drug safety ,loading drug dose ,creatinine blood level ,Gram negative sepsis ,retrospective study ,Bacteremia ,blood culture ,intensive care unit ,mental disease ,sepsis ,meropenem ,polycyclic compounds ,cefoperazone plus sulbactam ,colistin ,APACHE ,adult ,nephrotoxicity ,creatinine ,Multi-Drug Resistant ,neurologic disease ,female ,risk factor ,monotherapy ,multicenter study (topic) ,disease severity ,tertiary care center ,lipids (amino acids, peptides, and proteins) ,tigecycline ,pathogen clearance ,Charlson Comorbidity Index ,seizure ,multi-drug resistant ,minimum inhibitory concentration ,piperacillin plus tazobactam ,visual disorder ,Article ,vertigo ,male ,multidrug resistance ,Sepsis ,Karabay O., BATIREL A., Balkan I. I. , AGALAR C., Akalin S., ALICI O., Alp E., ALTA F. A. , ALTIN N., Arslan F., et al., -EFFICACY OF COLISTIN AND NON-COLISTIN MONOTHERAPIES IN MULTI-DRUG RESISTANT ACINETOBACTER BAUMANNII BACTEREMIA/SEPSIS-, ACTA MEDICA MEDITERRANEA, cilt.30, ss.1137-1143, 2014 ,follow up ,controlled study ,human ,bacteremia ,treatment duration ,Colistin ,ataxia ,biochemical phenomena, metabolism, and nutrition ,Monotherapy ,bacterial infections and mycoses ,major clinical study ,multi drug resistant acinetobacter baumannii bacteremia ,drug efficacy ,treatment outcome ,bacteria ,Acinetobacter Baumannii ,imipenem - Abstract
WOS: 000364114800027, Objective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with MDR-AB from 27 tertiary-referral hospitals between January 2009 and December 2012 were included. Patients' data that were on either colistin monotherapy (CM) or non-colistin monotherapy (NCM) were compared. Mortality on Day 14 was the primary endpoint, whereas microbiological eradication and clinical outcome were the secondary ones. Results: Eighty-four cases were included in the study with 36 being in the CM group and 48 in the NCM group. Thirty-eight (452%) cases were male and the mean age was 602 years. The mean durations of pre-MDR-AB hospital stay and intensive care unit stay were 25.8 days and 20.9 days, respectively. All of the cases had fever (>38 degrees C). The mean Pitt bacteremia score (PBS) of the patients was calculated as 6.8, APACHE 2 score as 18.9 and the Charlson co-morbidity index (CCI) as 3.7 (CM: 3.6 vs. NCM: 3.9). Twenty (55.6%) cases in the CM group and 26 cases in the NCM group (542%) (p=0.81) died; 9 cases in the CM group (25%) and 16 cases in the NCM group (33 3%) had treatment failure (P=0.55). Bacteriological eradication was achieved in 20 (55.6%) cases in the CM group and in 36 cases (75%) in the NCM group (P=0.061). Conclusions: No significant difference could be identified between the colistin monotherapy and non-colistin monotherapy options in MDR-AB cases with respect to the results of efficacy and 14-day mortality.
- Published
- 2014
7. Comparison of colistin monotherapy and non-colistin combinations in the
- Author
-
Balkan, II, Batirel, A, Karabay, O, Agalar, C, Akalin, S, Alici, O, Alp, E, Altay, FA, Altin, N, Arslan, F, Aslan, T, Bekiroglu, N, Cesur, S, Celik, AD, Dogan, M, Durdu, B, Duygu, F, Engin, A, Engin, DO, Gonen, I, Guciu, E, Guven, T, Hatipogiu, CA, Hosoglu, S, Karahocagil, MK, Kilic, AU, Ormen, B, Ozdemir, D, Ozer, S, Oztoprak, N, Sezak, N, Turhan, V, Turker, N, and Yilmaz, H
- Subjects
Acinetobacter spp ,Blood stream infection ,colistin ,monotherapy ,multi drug resistant - Abstract
Objectives: To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A) . Materials and Methods: Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included. Primary End-Point: 14-day mortality. Secondary End-Points: Microbial eradication and clinical improvement. Results: Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis. Conclusion: No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.
- Published
- 2015
8. EFFICACY OF COLISTIN AND NON-COLISTIN MONOTHERAPIES IN MULTI-DRUG
- Author
-
Karabay, O, Batirel, A, Balkan, II, Agalar, C, Akalin, S, Alici, O, Alp, E, Alta, FA, Altin, N, Arslan, F, Aslan, T, Bekiroglu, N, Cesur, S, Celik, AD, Dogan, M, Durdu, B, Duygu, F, Engin, A, Engin, DO, Gonen, I, Guclui, E, Guven, T, Hatipoglu, CA, Hosoglu, S, Karahocagil, M, Kilic, AU, Ormen, B, Ozdemir, D, Ozer, S, Oztoprak, N, Sezak, N, Turhan, V, Turker, N, and Yilmaz, H
- Subjects
resistant ,sepsis ,Acinetobacter baumannii ,bacteremia ,colistin ,monotherapy ,multi-drug - Abstract
Objective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with MDR-AB from 27 tertiary-referral hospitals between January 2009 and December 2012 were included. Patients' data that were on either colistin monotherapy (CM) or non-colistin monotherapy (NCM) were compared. Mortality on Day 14 was the primary endpoint, whereas microbiological eradication and clinical outcome were the secondary ones. Results: Eighty-four cases were included in the study with 36 being in the CM group and 48 in the NCM group. Thirty-eight (452%) cases were male and the mean age was 602 years. The mean durations of pre-MDR-AB hospital stay and intensive care unit stay were 25.8 days and 20.9 days, respectively. All of the cases had fever (>38 degrees C). The mean Pitt bacteremia score (PBS) of the patients was calculated as 6.8, APACHE 2 score as 18.9 and the Charlson co-morbidity index (CCI) as 3.7 (CM: 3.6 vs. NCM: 3.9). Twenty (55.6%) cases in the CM group and 26 cases in the NCM group (542%) (p=0.81) died; 9 cases in the CM group (25%) and 16 cases in the NCM group (33 3%) had treatment failure (P=0.55). Bacteriological eradication was achieved in 20 (55.6%) cases in the CM group and in 36 cases (75%) in the NCM group (P=0.061). Conclusions: No significant difference could be identified between the colistin monotherapy and non-colistin monotherapy options in MDR-AB cases with respect to the results of efficacy and 14-day mortality.
- Published
- 2014
9. PV-6 Retrospective review of HIV infected patients: a study from Turkey
- Author
-
Kaptan, F., primary, Ormen, B., additional, Turker, N., additional, El, S., additional, Ural, S., additional, Vardar, I., additional, and Coskun, N.A., additional
- Published
- 2009
- Full Text
- View/download PDF
10. PXII-5 Five cases of Crimean-Congo hemorrhagic fever from western Anatolia, Turkey
- Author
-
Ormen, B., primary, Turker, N., additional, Ural, S., additional, El, S., additional, Kaptan, F., additional, Vardar, I., additional, and Coskun, N.A., additional
- Published
- 2009
- Full Text
- View/download PDF
11. PV-3 Non-Hodgkin lymphoma and tuberculosis in an AIDS patient
- Author
-
Kaptan, F., primary, Ural, S., additional, El, S., additional, Turker, N., additional, Ormen, B., additional, Vardar, I., additional, Coskun, N.A., additional, Dik, E., additional, Payzın, B., additional, and Bener, S., additional
- Published
- 2009
- Full Text
- View/download PDF
12. Recurrent rhabdomyolysis and mild acute renal failure associated with acute Brucella infection
- Author
-
Toprak, O., primary, Kaptan, F., additional, Cirit, M., additional, Ormen, B., additional, Uzum, A., additional, Ersoy, R., additional, and Turker, N., additional
- Published
- 2005
- Full Text
- View/download PDF
13. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: A Multicenter retrospective analysis
- Author
-
Tumer Guven, Nilgün Altın, Serife Akalin, Nefise Oztoprak, Derya Ozturk Engin, Salih Hosoglu, Davut Ozdemir, Fatma Aybala Altay, N. Turker, Aysegul Ulu Kilic, Ibak Gonen, Aygul Dogan Celik, Vedat Turhan, Oguz Karabay, Salih Cesur, Ozlem Alici, Bülent Durdu, Mustafa Dogan, Ilker Inanc Balkan, Nural Bekiroglu, Canan Agalar, Ferhat Arslan, Emine Alp, Mustafa Kasim Karahocagil, Fazilet Duygu, Serdar Özer, Ayse Batirel, Bahar Ormen, Ertugrul Guclu, Nurbanu Sezak, Turan Aslan, Aynur Engin, Cigdem Ataman Hatipoglu, Hava Yilmaz, DURDU, BÜLENT, [Balkan, Ilker Inanc] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey -- [Batirel, Ayse -- Ozer, Serdar] Kartal Dr Lutfi Kirdar Educ & Res Hosp, Istanbul, Turkey -- [Agalar, Canan -- Alici, Ozlem] Fatih Sultan Mehmet Educ & Res Hosp, Istanbul, Turkey -- [Arslan, Ferhat] Istanbul Medipol Univ, Fac Med, Istanbul, Turkey -- [Aslan, Turan] Bezmi Alem Univ, Fac Med, Istanbul, Turkey -- [Engin, Derya Ozturk] Haydarpasa Numune Educ & Res Hosp, Istanbul, Turkey -- [Bekiroglu, Nural] Marmara Univ, Fac Med, Istanbul, Turkey -- [Durdu, Bulent] Bakirkoy Sadi Konuk Educ & Res Hosp, Istanbul, Turkey -- [Turhan, Vedat] GATA Haydarpasa Educ & Res Hosp, Istanbul, Turkey -- [Karabay, Oguz -- Guciu, Ertugrul] Sakarya Univ, Fac Med, Sakarya, Turkey -- [Akalin, Serife] Pamukkale Univ, Fac Med, Denizli, Turkey -- [Alp, Emine -- Kilic, Aysegul Ulu] Erciyes Univ, Fac Med, Kayseri, Turkey -- [Altay, Fatma Aybala] Diskapi Educ & Res Hosp, Ankara, Turkey -- [Altin, Nilgun -- Cesur, Salih] Ankara Etlik Educ & Res Hosp, Ankara, Turkey -- [Celik, Aygul Dogan] Trakya Univ, Fac Med, Edirne, Turkey -- [Dogan, Mustafa] Namik Kemal Univ, Fac Med, Tekirdag, Turkey -- [Duygu, Fazilet] Gaziosmanpasa Univ, Fac Med, Tokat, Turkey -- [Engin, Aynur] Cumhuriyet Univ, Fac Med, Sivas, Turkey -- [Gonen, Ibak] Suleyman Demirel Univ, Fac Med, TR-32200 Isparta, Turkey -- [Guven, Tumer] Ankara Ataturk Educ & Res Hosp, Ankara, Turkey -- [Hatipogiu, Cigdem Ataman] Ankara Educ & Res Hosp, Ankara, Turkey -- [Hosoglu, Salih] Dicle Univ, Fac Med, Diyarbakir, Turkey -- [Karahocagil, Mustafa Kasim] Yuzuncu Yil Univ, Fac Med, Van, Turkey -- [Ormen, Bahar] Izmir Ataturk Educ & Res Hosp, Izmir, Turkey -- [Ozdemir, Davut -- Sezak, Nurbanu -- Turker, Nesrin] Duzce Univ, Educ & Res Hosp, Duzce, Turkey -- [Oztoprak, Nefise] Antalya Educ & Res Hosp, Antalya, Turkey -- [Yilmaz, Hava] Ondokuz Mayis Univ, Fac Med, Samsun, Turkey, Durdu, Bulent -- 0000-0002-0244-4006, Karabay, Oguz -- 0000-0003-0502-432X, altay, fatma aybala -- 0000-0002-7149-2968, OMÜ, Balkan, Ilker Inanc, Batirel, Ayse, Karabay, Oguz, Agalar, Canan, Akalin, Serife, Alici, Ozlem, Alp, Emine, Altay, Fatma Aybala, Altin, Nilgun, Arslan, Ferhat, Aslan, Turan, Bekiroglu, Nural, Cesur, Salih, Celik, Aygul Dogan, Dogan, Mustafa, Durdu, Bulent, Duygu, Fazilet, Engin, Aynur, Engin, Derya Ozturk, Gonen, Ibak, Guciu, Ertugrul, Guven, Tumer, Hatipogiu, Cigdem Ataman, Hosoglu, Salih, Karahocagil, Mustafa Kasim, Kilic, Aysegul Ulu, Ormen, Bahar, Ozdemir, Davut, Ozer, Serdar, Oztoprak, Nefise, Sezak, Nurbanu, Turhan, Vedat, Turker, Nesrin, Yilmaz, Hava, Balkan, II, Batirel, A, Karabay, O, Agalar, C, Akalin, S, Alici, O, Alp, E, Altay, FA, Altin, N, Arslan, F, Aslan, T, Bekiroglu, N, Cesur, S, Celik, AD, Dogan, M, Durdu, B, Duygu, F, Engin, A, Engin, DO, Gonen, I, Guciu, E, Guven, T, Hatipogiu, CA, Hosoglu, S, Karahocagil, MK, Kilic, AU, Ormen, B, Ozdemir, D, Ozer, S, Oztoprak, N, Sezak, N, Turhan, V, Turker, N, Yilmaz, H, Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü, Karabay, Oğuz, and Güçlü, Ertuğrul
- Subjects
Male ,Kaplan Meier method ,Turkey ,retrospective study ,proportional hazards model ,Antibiotics ,Bacteremia ,Comorbidity ,Tertiary Care Centers ,middle aged ,chi square distribution ,Pharmacology (medical) ,colistin ,comparative study ,APACHE ,Aged, 80 and over ,OUTCOMES ,Acinetobacter/*drug effects/pathogenicity ,Acinetobacter Infections/*drug therapy/microbiology/mortality ,Adolescent ,Adult ,Aged ,Anti-Bacterial Agents/adverse effects/*therapeutic use ,Bacteremia/*drug therapy/microbiology/mortality ,Chi-Square Distribution ,Colistin/adverse effects/*therapeutic use ,Drug Resistance, Multiple, Bacterial ,Drug Therapy, Combination ,Female ,Humans ,Kaplan-Meier Estimate ,Length of Stay ,Middle Aged ,Multivariate Ana ,adult ,Remission Induction ,Appropriate ,clinical trial ,ANTIMICROBIAL THERAPY ,multi drug resistant Acinetobacter spp ,antiinfective agent ,Pitt bacteremia score ,aged ,Impact ,multivariate analysis ,Sulbactam ,risk factor ,monotherapy ,pathogen clearance ,Baumannii Bacteremia ,hospitalization ,Acinetobacter Infections ,medicine.medical_specialty ,bloodstream infection ,Article ,multidrug resistance ,multidrug resistant Acinetobacter bloodstream infection ,human ,treatment failure ,Retrospective Studies ,Pharmacology ,Proportional hazards model ,microbiology ,medicine.disease ,major clinical study ,mortality ,disease assessment ,drug efficacy ,multicenter study ,RISK-FACTORS ,TIGECYCLINE ,Colistin ,Acinetobacter infection ,Pediatrics ,BAUMANNII BACTEREMIA ,Time Factors ,IMPACT ,very elderly ,Critically-Ill Patients ,Turkey (republic) ,Risk Factors ,time factor ,Risk-Factors ,pathogenicity ,Pharmacology & Pharmacy ,Univariate analysis ,biology ,Acinetobacter ,MATCHED COHORT ,Anti-Bacterial Agents ,Blood stream infection ,female ,Treatment Outcome ,young adult ,tertiary care center ,CRITICALLY-ILL PATIENTS ,Charlson Comorbidity Index ,medicine.drug ,Research Article ,combination drug therapy ,medicine.drug_class ,Outcomes ,Young Adult ,remission ,length of stay ,Internal medicine ,Gram-Negative Bacteria ,medicine ,follow up ,controlled study ,GRAM-NEGATIVE BACTERIA ,A Multicenter retrospective analysis-, INDIAN JOURNAL OF PHARMACOLOGY, cilt.47, ss.95-100, 2015 [Balkan I. I. , BATIREL A., Karabay O., AGALAR C., Akalin S., ALICI O., Alp E., ALTAY F. A. , ALTIN N., Arslan F., et al., -Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections] ,Proportional Hazards Models ,Antimicrobial Therapy ,business.industry ,Retrospective cohort study ,Multi drug resistant Acinetobacter spp ,biology.organism_classification ,drug effects ,Multivariate Analysis ,business - Abstract
WOS: 000349144300018, PubMed ID: 25821319, Objectives: To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A) . Materials and Methods: Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included. Primary End-Point: 14-day mortality. Secondary End-Points: Microbial eradication and clinical improvement. Results: Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis. Conclusion: No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.
- Published
- 2015
14. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections
- Author
-
Turan Aslan, Cigdem Ataman Hatipoglu, Emine Alp, S. Cesur, Davut Ozdemir, N. Turker, Nilgün Altın, Ertugrul Guclu, Aysegul Ulu Kilic, Ilker Inanc Balkan, Salih Hosoglu, Nurbanu Sezak, Hava Yilmaz, Nefise Oztoprak, Tumer Guven, Serdar Özer, Bahar Ormen, Ayse Batirel, Derya Ozturk Engin, Aynur Engin, Ozlem Alici, Nuray Bekiroglu, Fazilet Duygu, Canan Agalar, Ibak Gonen, Mustafa Kasim Karahocagil, Oguz Karabay, Aygul Dogan Celik, Serife Akalin, Bülent Durdu, Mustafa Dogan, Ferhat Arslan, Fatma Aybala Altay, Vedat Turhan, Ondokuz Mayıs Üniversitesi, [Batirel, A. -- Ozer, S.] Kartal Dr Lutfi Kirdar Educ & Res Hosp, TR-34890 Istanbul, Turkey -- [Balkan, I. I.] Istanbul Univ, Cerrahpasa Med Fac, Istanbul, Turkey -- [Karabay, O. -- Guclu, E.] Sakarya Univ, Fac Med, Sakarya, Turkey -- [Agalar, C. -- Alici, O.] Fatih Sultan Mehmet Educ & Res Hosp, Istanbul, Turkey -- [Akalin, S.] Pamukkale Univ, Fac Med, Denizli, Turkey -- [Alp, E. -- Kilic, A. U.] Erciyes Univ, Fac Med, Kayseri, Turkey -- [Altay, F. A.] Diskapi Educ & Res Hosp, Ankara, Turkey -- [Altin, N. -- Cesur, S.] Ankara Etlik Educ & Res Hosp, Ankara, Turkey -- [Arslan, F.] Istanbul Medipol Univ, Fac Med, Istanbul, Turkey -- [Aslan, T.] Bezmi Alem Univ, Fac Med, Istanbul, Turkey -- [Bekiroglu, N.] Marmara Univ, Fac Med, Istanbul, Turkey -- [Celik, A. D.] Trakya Univ, Fac Med, Edirne, Turkey -- [Dogan, M.] Namik Kemal Univ, Fac Med, Tekirdag, Turkey -- [Durdu, B.] Bakirkoy Sadi Konuk Educ & Res Hosp, Istanbul, Turkey -- [Duygu, F.] Gaziosmanpasa Univ, Fac Med, Tokat, Turkey -- [Engin, A.] Cumhuriyet Univ, Fac Med, Sivas, Turkey -- [Engin, D. O.] Haydarpasa Numune Educ & Res Hosp, Istanbul, Turkey -- [Gonen, I.] Suleyman Demirel Univ, Fac Med, TR-32200 Isparta, Turkey -- [Guven, T.] Ankara Ataturk Educ & Res Hosp, Ankara, Turkey -- [Hatipoglu, C. A.] Ankara Educ & Res Hosp, Ankara, Turkey -- [Hosoglu, S.] Dicle Univ, Fac Med, Diyarbakir, Turkey -- [Karahocagil, M. K.] Yuzuncu Yil Univ, Fac Med, Van, Turkey -- [Ormen, B.] Izmir Ataturk Educ & Res Hosp, Izmir, Turkey -- [Ozdemir, D. -- Sezak, N. -- Turker, N.] Duzce Univ, Educ & Res Hosp, Duzce, Turkey -- [Oztoprak, N.] Antalya Educ & Res Hosp, Antalya, Turkey -- [Turhan, V.] GATA Haydarpasa Educ & Res Hosp, Istanbul, Turkey -- [Yilmaz, H.] Ondokuz Mayis Univ, Fac Med, Samsun, Turkey, altay, fatma aybala -- 0000-0002-7149-2968, Karabay, Oguz -- 0000-0003-0502-432X, Durdu, Bulent -- 0000-0002-0244-4006, and DURDU, BÜLENT
- Subjects
Acinetobacter baumannii ,Male ,retrospective study ,Bacteremia ,intensive care unit ,law.invention ,meropenem ,amikacin ,neurotoxicity ,middle aged ,colistin ,comparative study ,health care economics and organizations ,APACHE ,APACHE II ,adult ,clinical trial ,General Medicine ,Sulbactam ,Pitt bacteremia score ,microbial sensitivity test ,aged ,priority journal ,risk factor ,drug withdrawal ,monotherapy ,Drug Therapy, Combination ,tigecycline ,Acinetobacter Infections ,Colistin Plus ,Microbiology (medical) ,survival rate ,medicine.medical_specialty ,education ,drug combination ,bloodstream infection ,Microbial Sensitivity Tests ,gentamicin ,piperacillin plus tazobactam ,concurrent infection ,Colistin-Sulbactam ,multidrug resistance ,Humans ,human ,drug dose reduction ,propensity score ,Aged ,Retrospective Studies ,scoring system ,treatment response ,social sciences ,Length of Stay ,major clinical study ,mortality ,drug efficacy ,multicenter study ,Carbapenems ,Colistin ,eradication therapy ,loading drug dose ,Tigecycline ,rifampicin ,law ,Risk Factors ,Drug Resistance, Multiple, Bacterial ,biology ,Mortality rate ,nephrotoxicity ,article ,Middle Aged ,carbapenem derivative ,Intensive care unit ,aminoglycoside antibiotic agent ,humanities ,Infectious Diseases ,female ,Treatment Outcome ,Colistin-Carbapenem ,Female ,Charlson Comorbidity Index ,medicine.drug ,Adult ,sultamicillin ,doripenem ,netilmicin ,carbapenem ,length of stay ,Internal medicine ,medicine ,nonhuman ,business.industry ,isolation and purification ,Acinetobacter ,biology.organism_classification ,Surgery ,Antibacterial ,drug effects ,business ,human activities ,imipenem - Abstract
23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) -- 41394 -- Berlin, GERMANY, WOS: 000338723600006, PubMed ID: 24532009, The purpose of this investigation was to compare the efficacy of colistin-based therapies in extremely drug-resistant Acinetobacter spp. bloodstream infections (XDR-ABSI). A retrospective study was conducted in 27 tertiary-care centers from January 2009 to August 2012. The primary end-point was 14-day survival, and the secondary end-points were clinical and microbiological outcomes. Thirty-six and 214 patients [102 (47.7 %): colistin-carbapenem (CC), 69 (32.2 %): colistin-sulbactam (CS), and 43 (20.1 %: tigecycline): colistin with other agent (CO)] received colistin monotherapy and colistin-based combinations, respectively. Rates of complete response/cure and 14-day survival were relatively higher, and microbiological eradication was significantly higher in the combination group. Also, the in-hospital mortality rate was significantly lower in the combination group. No significant difference was found in the clinical (p = 0.97) and microbiological (p = 0.92) outcomes and 14-day survival rates (p = 0.79) between the three combination groups. Neither the timing of initial effective treatment nor the presence of any concomitant infection was significant between the three groups (p > 0.05) and also for 14-day survival (p > 0.05). Higher Pitt bacteremia score (PBS), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Charlson comorbidity index (CCI), and prolonged hospital and intensive care unit (ICU) stay before XDR-ABSI were significant risk factors for 14-day mortality (p = 0.02, p = 0.0001, p = 0.0001, p = 0.02, and p = 0.01, respectively). In the multivariable analysis, PBS, age, and duration of ICU stay were independent risk factors for 14-day mortality (p < 0.0001, p < 0.0001, and p = 0.001, respectively). Colistin-based combination therapy resulted in significantly higher microbiological eradication rates, relatively higher cure and 14-day survival rates, and lower in-hospital mortality compared to colistin monotherapy. CC, CS, and CO combinations for XDR-ABSI did not reveal significant differences with respect to 14-day survival and clinical or microbiological outcome before and after propensity score matching (PSM). PBS, age, and length of ICU stay were independent risk factors for 14-day mortality.
- Published
- 2014
15. Letter: Predictive Value of C-Reactive Protein to Albumin Ratio for Amputation Risk in Diabetic Foot Infection: Reply.
- Author
-
Karaca B, Kiris T, Ormen B, and Sener A
- Published
- 2024
- Full Text
- View/download PDF
16. Predictive Value of C-Reactive Protein to Albumin Ratio for Amputation Risk in Diabetic Foot Infection.
- Author
-
Karaca B, Ormen B, Kiris T, and Sener A
- Abstract
Diabetic foot infections are one of the complications of diabetes mellitus resulting in extremity amputation and mortality. This study aimed to examine the predictive value of the C-reactive protein (CRP) to albumin ratio (CAR) for amputation risk in diabetic foot infection. Data from 178 patients were retrospectively examined. We found the cut point value of 15.45 according to the receiver operating characteristic (ROC) curve to show the predictive value of CAR for amputation risk in the overall population. We then divided the patients into two groups low (<15.45, n = 96) and high risk (≥15.45, n = 82) according to their CAR value. Matching based on propensity scores produced 64 patients in each group and showed that the amputation rate was high in the high-risk groups (50 vs 25%, P = .003). In the multivariate analysis in the matching group, previous amputation, antibiotic therapy in the last 3 months, and CAR (Odds ratio [OR]: 1.30, 95%Confidence interval [CI]: 1.01-1.45, P < .001) were independent predictors of amputation. These parameters may be useful to predict amputation risk in these patient groups., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflict of interest concerning the research, authorship, and/or publication of this article.
- Published
- 2023
- Full Text
- View/download PDF
17. Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter ephesus study.
- Author
-
Sipahi OR, Akyol D, Ormen B, Cicek-Senturk G, Mermer S, Onal U, Amer F, Saed MA, Ozdemir K, Tukenmez-Tigen E, Oztoprak N, Altin U, Kurtaran B, Popescu CP, Sakci M, Suntur BM, Gautam V, Sharma M, Kaya S, Akcil EF, Kaya S, Turunc T, Ergen P, Kandemir O, Cesur S, Bardak-Ozcem S, Ozgiray E, Yurtseven T, Erdem HA, Sipahi H, Arda B, Pullukcu H, Tasbakan M, Yamazhan T, Aydemir S, and Ulusoy S
- Subjects
- Humans, Meropenem therapeutic use, Cefepime therapeutic use, Ceftazidime therapeutic use, Retrospective Studies, Anti-Bacterial Agents therapeutic use, Bacteria, Staphylococcus, Delivery of Health Care, Ampicillin, Vancomycin therapeutic use, Meningitis drug therapy
- Abstract
Background: Herein, we analyzed the efficacy of main antibiotic therapy regimens in the treatment of healthcare-associated meningitis (HCAM)., Materials/methods: This retrospective cohort study was conducted in 18 tertiary-care academic hospitals Turkey, India, Egypt and Romania. We extracted data and outcomes of all patients with post-neurosurgical meningitis cases fulfilling the study inclusion criteria and treated with empirical therapy between December 2006-September 2018., Results: Twenty patients in the cefepime + vancomycin-(CV) group, 31 patients in the ceftazidime + vancomycin-(CFV) group, and 119 patients in the meropenem + vancomycin-(MV) group met the inclusion criteria. The MV subgroup had a significantly higher mean Glasgow Coma Score, a higher rate of admission to the intensive care unit within the previous month, and a higher rate of antibiot herapy within the previous month before the meningitis episode (p < 0.05). Microbiological success on Day 3-5, end of treatment (EOT) clinical success (80% vs. 54.8%% vs 57.9%), and overall success (EOT success followed by one-month survival without relapse or reinfection 65% vs. 51.6% vs. 45.3%), EOT all cause mortality (ACM) and day 30 ACM (15% vs. 22.6% vs. 26%) did not differ significantly (p > 0.05) among the three cohorts. No regimen was effective against carbapenem-resistant bacteria, and vancomycin resulted in an EOT clinical success rate of 60.6% in the methicillin-resistant staphylococci or ampicillin-resistant enterococci subgroup (n = 34)., Conclusions: Our study showed no significant difference in terms of clinical success and mortality among the three treatment options. All regimens were ineffective against carbapenem-resistant bacteria. Vancomycin was unsuccessful in approximately 40% of cases involving methicillin-resistant staphylococci or ampicillin-resistant enterococci., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
18. Are bacterial coinfections really rare in COVID-19 intensive care units?
- Author
-
Karaca B, Aksun M, Karahan NA, Girgin S, Ormen B, Tuzen AS, Demirdal T, and Sencan A
- Subjects
- Humans, Retrospective Studies, Intensive Care Units, Prognosis, COVID-19 epidemiology, Coinfection epidemiology, Shock, Septic
- Abstract
Objectives: There are limited data about nosocomial coinfections of COVID-19 cases monitored in the intensive care unit. This study aims to investigate coinfections in COVID-19 patients followed in an intensive care unit of a university hospital., Methods: This study analyzed retrospectively the data of coinfections of 351 COVID-19 patients in the period 28.02.2020-15.01.2021 in a tertiary care intensive care unit in a university hospital., Results: Bacterial coinfections were present in 216 of the 351 cases. One hundred and thirty of these cases were evaluated as nosocomial infections. On the third day the Sequential Organ Failure Assessment Score, usage of invasive mechanical ventilation and presence of septic shock were significantly higher in the coinfected group. The neutrophil/lymphocyte ratio, polymorphonuclear leukocyte count, procalcitonin, ferritin, and blood urea nitrogen values were significantly higher in the coinfection group. White blood cells (WBC) (OR: 1.075, 95% CI 1.032-1.121, p = 0.001) and ICU hospitalization day (OR: 1.114, 95% CI 1.063-1.167, p < 0.001) were found to be independent risk factors for coinfection in the multivariate logistic regression analysis. The rates of hospitalization day on the day of arrival, the 21st day, as well as total mortality (p = 0.004), were significantly higher in the coinfected group., Conclusion: Bacterial coinfections of COVID-19 patients in the intensive care unit remain a problem. Identifying the infectious agent, classifying colonizations and infections, and using the proper treatment of antibiotics are of great importance in the case management of COVID-19 patients in the intensive care unit., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
19. Variables determining mortality in patients with Acinetobacter baumannii meningitis/ventriculitis treated with intrathecal colistin.
- Author
-
Ceylan B, Arslan F, Sipahi OR, Sunbul M, Ormen B, Hakyemez İN, Turunc T, Yıldız Y, Karsen H, Karagoz G, Tekin R, Hizarci B, Turhan V, Senol S, Oztoprak N, Yılmaz M, Ozdemir K, Mermer S, Kokoglu OF, and Mert A
- Subjects
- Acinetobacter Infections epidemiology, Adult, Aged, Anti-Bacterial Agents administration & dosage, Case-Control Studies, Cerebral Ventriculitis epidemiology, Colistin administration & dosage, Female, Humans, Injections, Spinal, Male, Meningitis, Bacterial epidemiology, Meropenem, Middle Aged, Retrospective Studies, Thienamycins administration & dosage, Young Adult, Acinetobacter Infections mortality, Acinetobacter baumannii pathogenicity, Anti-Bacterial Agents pharmacology, Cerebral Ventriculitis mortality, Colistin pharmacology, Meningitis, Bacterial mortality, Outcome Assessment, Health Care, Thienamycins pharmacology
- Abstract
Aim: To examine the variables associated with mortality in patients with Acinetobacter baumannii-related central nervous system infections treated with intrathecal colistin., Materials and Methods: This multi-centre retrospective case control study included patients from 11 centres in Turkey, as well as cases found during a literature review. Only patients with CNS infections caused by multidrug-resistant or extensively drug-resistant Acinetobacter baumannii treated with intrathecal colistin were included in this study. The variables associated with mortality were determined by dividing the patients into groups who died or survived during hospitalisation, and who died or survived from Acinetobacter meningitis., Results: Among the 77 cases enrolled in the study, 35 were found through a literature review and 42 were cases from our centres. Forty-four cases (57.1%) were male and the median age was 48 years (range: 20-78 years). Thirty-seven patients (48%) died during hospitalisation. The variables associated with increased all-cause mortality during hospitalisation included old age (odds ratio, 1.035; 95% confidence interval (CI), 1.004-1.067; p=0.026) and failure to provide cerebrospinal fluid sterilisation (odds ratio, 0.264; 95% confidence interval, 0.097-0.724; p=0.01). There is a trend (P=0.062) towards higher mortality with using of meropenem during meningitis treatment. Fifteen cases (19%) died from meningitis. There were no significant predictors of meningitis-related mortality., Conclusions: The mortality rate for central nervous system infections caused by multidrug-resistant or extensively drug-resistant Acinetobacter baumannii is high. Old age and failure to provide CSF sterilisation are associated with increased mortality during hospitalisation., (Copyright © 2016. Published by Elsevier B.V.)
- Published
- 2017
- Full Text
- View/download PDF
20. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.
- Author
-
Balkan II, Batirel A, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, and Yilmaz H
- Subjects
- APACHE, Acinetobacter pathogenicity, Acinetobacter Infections microbiology, Acinetobacter Infections mortality, Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents adverse effects, Bacteremia microbiology, Bacteremia mortality, Chi-Square Distribution, Colistin adverse effects, Comorbidity, Drug Therapy, Combination, Female, Humans, Kaplan-Meier Estimate, Length of Stay, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Remission Induction, Retrospective Studies, Risk Factors, Tertiary Care Centers, Time Factors, Treatment Outcome, Turkey, Young Adult, Acinetobacter drug effects, Acinetobacter Infections drug therapy, Anti-Bacterial Agents therapeutic use, Bacteremia drug therapy, Colistin therapeutic use, Drug Resistance, Multiple, Bacterial
- Abstract
Objectives: To compare the efficacy of colistin (COL) monotherapy versus non-COL based combinations in the treatment of bloodstream infections (BSIs) due to multidrug resistant Acinetobacter spp.(MDR-A)., Materials and Methods: Retrospective data of 107 MDR-A BSI cases from 27 tertiary centers in Turkey were included., Primary End-Point: 14-day mortality., Secondary End-Points: Microbial eradication and clinical improvement., Results: Thirty-six patients in the COL monotherapy (CM) group and 71 in the non-COL based combinations (NCC) group were included in the study. Mean age was 59.98 ± 20 years (range: 18-89) and 50.5% were male. Median duration of follow-up was 40 days (range: 9-297). The 14-day survival rates were 52.8% in CM and 47.23% in NCC group (P = 0.36). Microbiological eradication was achieved in 69% of CM and 83% of NCC group (P = 0.13). Treatment failure was detected in 22.9% of cases in both CM and NCC groups. Univariate analysis revealed that mean age (P = 0.001), Charlson comorbidity index (P = 0.03), duration of hospital stay before MDR-A BSI (P = 0.04), Pitt bacteremia score (P = 0.043) and Acute Physiology and Chronic Health Evaluation II score (P = 0.05) were significant in terms of 14-day mortality. Advanced age (P = 0.01) and duration of hospital stay before MDR-A BSI (P = 0.04) were independently associated with 14-day mortality in multivariate analysis., Conclusion: No significant difference was detected between CM and non-COL based combinations in the treatment of MDR-A BSIs in terms of efficacy and 14-day mortality.
- Published
- 2015
- Full Text
- View/download PDF
21. Gemella morbillorum Endocarditis.
- Author
-
Ural S, Gul Yurtsever S, Ormen B, Turker N, Kaptan F, El S, Akyildiz ZI, and Coskun NA
- Abstract
Infective endocarditis caused by Gemella morbillorum is a rare disease. In this report 67-year-old male patient with G. morbillorum endocarditis was presented. The patient was hospitalized as he had a fever of unknown origin and in the two of the three sets of blood cultures taken at the first day of hospitalization G. morbillorum was identified. The transthoracic echogram revealed 14 × 10 mm vegetation on the aortic noncoronary cuspis. After 4 weeks of antibiotic therapy, the case was referred to the clinic of cardiovascular surgery for valve surgery.
- Published
- 2014
- Full Text
- View/download PDF
22. [Molecular characterization of complex recombinant HIV-1 CRF06_cpx subtype detected in Turkey].
- Author
-
Sayan M, Kaptan F, Ormen B, and Türker N
- Subjects
- Adult, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Drug Resistance, Viral genetics, Female, HIV Antibodies blood, HIV Protease Inhibitors pharmacology, HIV-1 drug effects, HIV-1 genetics, HIV-1 isolation & purification, Humans, Male, Microbial Sensitivity Tests, Mutation, Phylogeny, RNA, Viral blood, Reverse Transcriptase Inhibitors pharmacology, Turkey, pol Gene Products, Human Immunodeficiency Virus chemistry, pol Gene Products, Human Immunodeficiency Virus genetics, HIV Infections virology, HIV-1 classification
- Abstract
A major proportion of the global HIV infections is caused by group M of HIV-1 genotype and to date approximately nine subtypes (A, B, C, D, F, G, H, J, K) and 50 circulating recombinant forms (CRFs) have been recognized. Recombinants between different HIV-1 group M subtypes are designated as CRF. The extension 'cpx', for complex, is given if the CRF consists of contributions from three or more different subtypes but the composition of the subtype is not given. The objective of this study was to present, for the first time an HIV-1 positive married couple infected with CRF06_cpx subtype in Izmir, Turkey. A 39-year-old male patient who admitted to hospital with the complaints of oral candidiasis and zona, was found to be anti-HIV positive. CD4+ T lymphocyte count was 21 cells/mm3 and plasma HIV-1 RNA level was 56.380 copies/ml. He reported unprotected heterosexual contact with multiple partners including African women during his stay in Saudi Arabia between 1996 and 2002. After his diagnosis, his 37-year-old wife was screened for HIV infection and she was also found anti-HIV positive, with CD4+ T cell count of 122 cells/mm3. However, her results of basal plasma HIV-1 RNA could not be obtained because of an internal control error. HIV-1 strains were analysed for subtyping, recombination and drug resistance mutations with pol gene region sequencing. HIV-1 sequences were subtyped as CRF06_cpx after phylogenetic analysis using neighbor-joining method. According to the recombination analysis, HIV-1 pol gene regions consisted of group M subtype G, A, D, and B in the male patient and G K, A, F, and D in the female patient. While L10I + L33F mutation associated with protease inhibitor (PI) resistance was detected in both of the patients, K219N mutation associated with nucleoside reverse transcriptase inhibitor (NRTI) resistance was detected only in the male patient. In conclusion, HIV-1 molecular epidemiology studies are important tools for tracking transmission patterns and the spread of CRF. Global monitoring of CRF subtypes is also important to supply data for HIV vaccine development studies. On the other hand, the detection of HIV-1 primary resistance mutations in antiretroviral naive patients suggested that the resistance testing should be an integral part of the management of HIV infection.
- Published
- 2014
23. [Attitudes and side effects related to pandemic influenza A (H1N1) vaccination in healthcare personnel].
- Author
-
Ormen B, Türker N, Vardar I, Kaptan F, El S, Ural S, Kaya F, and Coşkun NA
- Subjects
- Adolescent, Adult, Female, Humans, Influenza, Human epidemiology, Influenza, Human psychology, Male, Middle Aged, Surveys and Questionnaires, Turkey epidemiology, Vaccination adverse effects, Young Adult, Attitude of Health Personnel, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines adverse effects, Influenza, Human prevention & control, Pandemics prevention & control, Vaccination psychology
- Abstract
The aims of this study were to evaluate the attitudes towards H1N1 vaccination and to determine the safety and side effects following 2009 pandemic influenza A (H1N1) vaccination. Pandemic influenza vaccine had been administered to the healthcare personnel in our research and training hospital in December 2009. The rate being vaccinated was established as 40% (800/2000). Four months following vaccination, the opinions about vaccination were asked to the healthcare workers, and also side effects were questioned to the vaccinated group. Two different questionnaires (for vaccinated and unvaccinated subjects) were delivered to the volunteers who agreed to participate in the study. Demographic features, reasons related to being vaccinated or not, were questioned. The vaccinated group was also questioned for the presence of chronic diseases, previous vaccinations (pandemic/seasonal influenza), local or systemic reactions that develop after vaccination. A total of 332 volunteers participated in the questionnaire. Of them 247 (74.4%) were vaccinated and 85 (25.6%) were unvaccinated. Male/female ratio of the participants was 1.2, and 55.7% of them were older than 30-year-old. Most of the participants (82.8%) were highly educated (high school and faculty-graduated). Vaccination rates were found statistically significant in advanced age group compared to young adults (p= 0.042); in male gender compared to females (p= 0.001) and in parents compared to subjects who didn't have children (p= 0.021). Vaccination rates were observed to be higher (57.5%) in non-medical staff (cleaning employers, administrative personnel, etc.) than the physicians (29.1%) and nurses (13.4%), and the rate was also high (54.7%) in personnel who worked in intensive care units, emergency department and administrative units than the personnel who worked in the clinics of internal medicine (22.3%) and surgery (23.1%) (p= 0.001). The most important causes of rejecting vaccination were being afraid of the side effects (69.4%) and not believing the effectiveness of the vaccine (56.4%). The leading causes of accepting vaccination were worries about infecting their family (60.3%) and being in a risk group (54.3%). After vaccination, local reactions (pain, swelling and redness at the vaccination site) were described in 43.3% and systemic reactions (weakness, fatigue, muscle aches, influenza-like symptoms, etc.) were described in 43.7% of the subjects. Severe side effects such as vasculitis, neuritis, encephalomyelitis, Guillian-Barre syndrome and anaphylactic reaction were not observed in any of the vaccinated cases. It was detected that worries about the safety of vaccine had negative impact for vaccination. Since no serious side effects were detected related to vaccination, it was concluded that the vaccine was safe. In spite of the scientific proofs, negative concerns about the safety of the vaccines can unfavorably affect the vaccination campaigns and can jeopardize efforts of influenza control. As a result, data collection systems about the safety and side effects of the vaccine all over the country and regular reports about these data may more efficiently guide vaccination programs in the future.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.